<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080623</url>
  </required_header>
  <id_info>
    <org_study_id>D161100000816006</org_study_id>
    <nct_id>NCT03080623</nct_id>
  </id_info>
  <brief_title>Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion</brief_title>
  <official_title>Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposed to construct an ultrasound-based diagnostic model for Differentiating&#xD;
      Malignant Breast Lesion From Benign Lesion. This study contains both retrospective and&#xD;
      prospective part, which are designed for model construction and independent validation,&#xD;
      respectively.This study aims to construct an easy-to-use ultrasound-based model, prove the&#xD;
      efficacy of the model for identifying malignant breast lesion from benign lesion, and finally&#xD;
      promote the application of this diagnostic model in more clinics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>breast biopsy proved malignant or benign lesion</measure>
    <time_frame>between breast ultrasound and biopsy(one week)</time_frame>
    <description>for patients regarded as malignant by the breast ultrasound, breast biopsy results are used as reference test, which determines the breast lesion is malignant or benign</description>
  </primary_outcome>
  <primary_outcome>
    <measure>two breast ultrasound identified benign lesion</measure>
    <time_frame>between first detection of breast lesion and the second ultrasound(six month)</time_frame>
    <description>for patients regarded as benign by the breast ultrasound, they will receive a second breast ultrasound after six month(this is regular examination for patients with first detected breast lesion). If the second ultrasound indicates benign, the lesion will be regarded as benign</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1981</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Suspicious breast lesions</arm_group_label>
    <description>women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasoundï¼Œpatients will be assigned to breast biopsy or follow-up</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Breast biopsy pathology&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        females with breast lesion who need to receive breast ultrasound to make differential&#xD;
        diagnosis of benign and malignant lesion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female&#xD;
&#xD;
          -  with single breast lesion(maximum diameter&gt;0.8 cm)&#xD;
&#xD;
          -  agree to receive follow-up in six months and take the second breast ultrasound six&#xD;
             month after the first breast ultrasound, if a benign diagnosis is achieved at the&#xD;
             first ultrasound&#xD;
&#xD;
          -  sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lost to follow-up&#xD;
&#xD;
          -  failed to take the second breast ultrasound six month after the first breast&#xD;
             ultrasound&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Ouyang</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haidian women and children's hospital of beijing</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shunyi women and children's hospital of Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Heibei Medical Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Tao OUYANG</investigator_full_name>
    <investigator_title>Chairman of Breast Center of Beijing Cancer Hospital</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

